



## Regor Therapeutics Group and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders

### Torreya advised Regor on the transaction

Shanghai, China & Indianapolis, Indiana, December 16, 2021

Eli Lilly and Company (NYSE: LLY, "Lilly") and Regor Therapeutics Group ("Regor") have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders.

Under the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan, where Regor will maintain these rights and responsibilities. The agreement will allow each company the opportunity to fully leverage both parties' existing compounds and technologies globally to maximize patient treatment choice.

Regor will receive an upfront payment of up to \$50 million, which partially includes an equity investment by Lilly in Regor, subject to the parties entering into standard equity agreements. The company is also eligible to receive up to \$1.5 billion in potential payments based on the achievement of prespecified preclinical, clinical development and commercial milestones, as well as tiered royalties from low-single to low-double digits on sales resulting from the agreement.

Torreya advised Regor on this transaction, which is the largest preclinical outlicensing transaction from China to date. Torreya has advised on 18 transactions involving Chinese pharmaceutical companies since January 2018.

### ABOUT REGOR THERAPEUTICS GROUP:

For more information about Regor, please see: [www.regor.com](http://www.regor.com)

### ABOUT ELI LILLY AND COMPANY:

For more information about Lilly, please see: [www.lilly.com](http://www.lilly.com)

### Deal Press Release



Regor Therapeutics Group

Strategic collaboration to discover and develop novel therapies for metabolic disorders with

Up to \$1.5 billion  
December 2021

### Torreya Contacts

JIE LIU

Managing Director | New York Office

[jie.liu@torreya.com](mailto:jie.liu@torreya.com) | 917.683.4003 | [BIO](#)

Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 15 Stratford Place, London W1C 1BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.